Two cross-sectional studies reported higher rather than lower systemic levels of IL-22 in patients with type 2 diabetes and in patients with coronary artery disease from hospital-based samples than in healthy controls [9, 10], but population-based data or prospective studies on IL-22 and cardiometabolic diseases are not available. This evidence concerns the gene IL22 and type 2 diabetes mellitus.